Effectiveness of integrase strand transfer inhibitors in HIV-infected treatment-experienced individuals across Europe
Autor(a) principal: | |
---|---|
Data de Publicação: | 2022 |
Outros Autores: | , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10362/143388 |
Resumo: | Funding Information: The INTEGRATE project received an unconditioned grant from Gilead Sciences Europe Ltd. This study was also funded by the Swedish Research Council (2016‐01675, to AS), the European Union by the CARE H2020 project (under grant agreement no. 825673) and Stockholm County Council (ALF 20190451 and CIMED 20200645; to AS), and the Fundação para a Ciência e Tecnologia, Portugal (INTEGRIV Project PTDC/SAU‐INF/31990/20170 and GHTM‐UID/Multi/04413/2013; to AA). Funding Information: The INTEGRATE project received an unconditioned grant from Gilead Sciences Europe Ltd. This study was also funded by the Swedish Research Council (2016-01675, to AS), the European Union by the CARE H2020 project (under grant agreement no. 825673) and Stockholm County Council (ALF 20190451 and CIMED 20200645; to AS), and the Fundação para a Ciência e Tecnologia, Portugal (INTEGRIV Project PTDC/SAU-INF/31990/20170 and GHTM-UID/Multi/04413/2013; to AA). The INTEGRATE study group: A. Abecasis, Global Health and Tropical Medicine (GHTM), Instituto de Higiene e Medicina Tropical - Universidade Nova de Lisboa, Lisbon, Portugal M. Bobkova, Gamaleya Federal Center for Epidemiology and Microbiology of Russia C. Seguin-Devaux, Department of Infection and Immunity, Luxembourg Institute of Health, Luxembourg M. Fabbiani, University Hospital of Siena, Siena, Italy F. Garcia, Hospital Universitario San Cecilio, Granada, Spain A. M. Geretti, University of Liverpool, UK P. Gomes, Laboratório de Biologia Molecular (LMCBM, SPC, CHLO-HEM), Lisbon, Portugal and Centro de Investigação Interdisciplinar Egas Moniz (CiiEM), Instituto Universitário Egas Moniz, Caparica, Portugal F. Incardona, EuResist Network, Roma, Italy – IPRO, Roma, Italy R. Kaiser, University of Cologne, Cologne, Germany R. Paredes, Irsicaixa, Spain B. Rossetti, University Hospital of Siena, Siena, Italy M. Sayan, Kocaeli University, Medical Faculty, Turkey A. Sönnerborg, Karolinska Institutet, Stockholm, Sweden A. M. Vandamme, REGA Institut KU Leuven, Belgium M. Zazzi, University of Siena, Siena, Italy. Publisher Copyright: © 2022 British HIV Association. |
id |
RCAP_5a4b2979109e5fce4ff12f7d5cecc5d2 |
---|---|
oai_identifier_str |
oai:run.unl.pt:10362/143388 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Effectiveness of integrase strand transfer inhibitors in HIV-infected treatment-experienced individuals across EuropedolutegravireffectivenesselvitegravirHIVINSTIintegrase strand transfer inhibitorsraltegravirtreatment-experiencedHealth PolicyInfectious DiseasesPharmacology (medical)SDG 3 - Good Health and Well-beingFunding Information: The INTEGRATE project received an unconditioned grant from Gilead Sciences Europe Ltd. This study was also funded by the Swedish Research Council (2016‐01675, to AS), the European Union by the CARE H2020 project (under grant agreement no. 825673) and Stockholm County Council (ALF 20190451 and CIMED 20200645; to AS), and the Fundação para a Ciência e Tecnologia, Portugal (INTEGRIV Project PTDC/SAU‐INF/31990/20170 and GHTM‐UID/Multi/04413/2013; to AA). Funding Information: The INTEGRATE project received an unconditioned grant from Gilead Sciences Europe Ltd. This study was also funded by the Swedish Research Council (2016-01675, to AS), the European Union by the CARE H2020 project (under grant agreement no. 825673) and Stockholm County Council (ALF 20190451 and CIMED 20200645; to AS), and the Fundação para a Ciência e Tecnologia, Portugal (INTEGRIV Project PTDC/SAU-INF/31990/20170 and GHTM-UID/Multi/04413/2013; to AA). The INTEGRATE study group: A. Abecasis, Global Health and Tropical Medicine (GHTM), Instituto de Higiene e Medicina Tropical - Universidade Nova de Lisboa, Lisbon, Portugal M. Bobkova, Gamaleya Federal Center for Epidemiology and Microbiology of Russia C. Seguin-Devaux, Department of Infection and Immunity, Luxembourg Institute of Health, Luxembourg M. Fabbiani, University Hospital of Siena, Siena, Italy F. Garcia, Hospital Universitario San Cecilio, Granada, Spain A. M. Geretti, University of Liverpool, UK P. Gomes, Laboratório de Biologia Molecular (LMCBM, SPC, CHLO-HEM), Lisbon, Portugal and Centro de Investigação Interdisciplinar Egas Moniz (CiiEM), Instituto Universitário Egas Moniz, Caparica, Portugal F. Incardona, EuResist Network, Roma, Italy – IPRO, Roma, Italy R. Kaiser, University of Cologne, Cologne, Germany R. Paredes, Irsicaixa, Spain B. Rossetti, University Hospital of Siena, Siena, Italy M. Sayan, Kocaeli University, Medical Faculty, Turkey A. Sönnerborg, Karolinska Institutet, Stockholm, Sweden A. M. Vandamme, REGA Institut KU Leuven, Belgium M. Zazzi, University of Siena, Siena, Italy. Publisher Copyright: © 2022 British HIV Association.Objectives: To explore the effectiveness and durability of integrase strand transfer inhibitor (INSTI)-based regimens in pre-treated subjects. Methods: Treatment-experienced individuals starting an INSTI-based regimen during 2012–2019 were selected from the INTEGRATE collaborative study. The time to virological failure [VF: one measurement of viral load (VL) ≥ 1000 copies/mL or two ≥ 50 copies/ml or one VL measurement ≥ 50 copies/mL followed by treatment change] and to INSTI discontinuation were evaluated. Results: Of 13 560 treatments analysed, 4284 were from INSTI-naïve, non-viraemic (IN-NV) individuals, 1465 were from INSTI-naïve, viraemic (IN-V) individuals, 6016 were from INSTI-experienced, non-viraemic (IE-NV) individuals and 1795 were from INSTI-experienced, viraemic (IE-V) individuals. Major INSTI drug resistance mutations (DRMs) were previously detected in 4/519 (0.8%) IN-NV, 3/394 (0.8%) IN-V, 7/1510 (0.5%) IE-NV and 25/935 (2.7%) IE-V individuals. The 1-year estimated probabilities of VF were 3.1% [95% confidence interval (CI): 2.5–3.8] in IN-NV, 18.4% (95% CI: 15.8–21.2) in IN-V, 4.2% (95% CI: 3.6–4.9) in IE-NV and 23.9% (95% CI: 20.9–26.9) in IE-V subjects. The 1-year estimated probabilities of INSTI discontinuation were 12.1% (95% CI: 11.1–13.0) in IN-NV, 19.6% (95% CI: 17.5–21.6) in IN-V, 10.8% (95% CI: 10.0–11.6) in IE-NV and 21.7% (95% CI: 19.7–23.5) in IE-V subjects. Conclusions: Both VF and INSTI discontinuation occur at substantial rates in viraemic subjects. Detection of DRMs in a proportion of INSTI-experienced individuals makes INSTI resistance testing mandatory after failure.TB, HIV and opportunistic diseases and pathogens (THOP)Global Health and Tropical Medicine (GHTM)Instituto de Higiene e Medicina Tropical (IHMT)RUNEuResist Network, INTEGRATE study groupAbecasis, AnaGomes, PerpetuaVandamme, A. M.2022-08-30T22:38:15Z2022-082022-08-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article16application/pdfhttp://hdl.handle.net/10362/143388eng1464-2662PURE: 46201318https://doi.org/10.1111/hiv.13262info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-03-11T05:21:43Zoai:run.unl.pt:10362/143388Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T03:50:55.199062Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Effectiveness of integrase strand transfer inhibitors in HIV-infected treatment-experienced individuals across Europe |
title |
Effectiveness of integrase strand transfer inhibitors in HIV-infected treatment-experienced individuals across Europe |
spellingShingle |
Effectiveness of integrase strand transfer inhibitors in HIV-infected treatment-experienced individuals across Europe EuResist Network, INTEGRATE study group dolutegravir effectiveness elvitegravir HIV INSTI integrase strand transfer inhibitors raltegravir treatment-experienced Health Policy Infectious Diseases Pharmacology (medical) SDG 3 - Good Health and Well-being |
title_short |
Effectiveness of integrase strand transfer inhibitors in HIV-infected treatment-experienced individuals across Europe |
title_full |
Effectiveness of integrase strand transfer inhibitors in HIV-infected treatment-experienced individuals across Europe |
title_fullStr |
Effectiveness of integrase strand transfer inhibitors in HIV-infected treatment-experienced individuals across Europe |
title_full_unstemmed |
Effectiveness of integrase strand transfer inhibitors in HIV-infected treatment-experienced individuals across Europe |
title_sort |
Effectiveness of integrase strand transfer inhibitors in HIV-infected treatment-experienced individuals across Europe |
author |
EuResist Network, INTEGRATE study group |
author_facet |
EuResist Network, INTEGRATE study group Abecasis, Ana Gomes, Perpetua Vandamme, A. M. |
author_role |
author |
author2 |
Abecasis, Ana Gomes, Perpetua Vandamme, A. M. |
author2_role |
author author author |
dc.contributor.none.fl_str_mv |
TB, HIV and opportunistic diseases and pathogens (THOP) Global Health and Tropical Medicine (GHTM) Instituto de Higiene e Medicina Tropical (IHMT) RUN |
dc.contributor.author.fl_str_mv |
EuResist Network, INTEGRATE study group Abecasis, Ana Gomes, Perpetua Vandamme, A. M. |
dc.subject.por.fl_str_mv |
dolutegravir effectiveness elvitegravir HIV INSTI integrase strand transfer inhibitors raltegravir treatment-experienced Health Policy Infectious Diseases Pharmacology (medical) SDG 3 - Good Health and Well-being |
topic |
dolutegravir effectiveness elvitegravir HIV INSTI integrase strand transfer inhibitors raltegravir treatment-experienced Health Policy Infectious Diseases Pharmacology (medical) SDG 3 - Good Health and Well-being |
description |
Funding Information: The INTEGRATE project received an unconditioned grant from Gilead Sciences Europe Ltd. This study was also funded by the Swedish Research Council (2016‐01675, to AS), the European Union by the CARE H2020 project (under grant agreement no. 825673) and Stockholm County Council (ALF 20190451 and CIMED 20200645; to AS), and the Fundação para a Ciência e Tecnologia, Portugal (INTEGRIV Project PTDC/SAU‐INF/31990/20170 and GHTM‐UID/Multi/04413/2013; to AA). Funding Information: The INTEGRATE project received an unconditioned grant from Gilead Sciences Europe Ltd. This study was also funded by the Swedish Research Council (2016-01675, to AS), the European Union by the CARE H2020 project (under grant agreement no. 825673) and Stockholm County Council (ALF 20190451 and CIMED 20200645; to AS), and the Fundação para a Ciência e Tecnologia, Portugal (INTEGRIV Project PTDC/SAU-INF/31990/20170 and GHTM-UID/Multi/04413/2013; to AA). The INTEGRATE study group: A. Abecasis, Global Health and Tropical Medicine (GHTM), Instituto de Higiene e Medicina Tropical - Universidade Nova de Lisboa, Lisbon, Portugal M. Bobkova, Gamaleya Federal Center for Epidemiology and Microbiology of Russia C. Seguin-Devaux, Department of Infection and Immunity, Luxembourg Institute of Health, Luxembourg M. Fabbiani, University Hospital of Siena, Siena, Italy F. Garcia, Hospital Universitario San Cecilio, Granada, Spain A. M. Geretti, University of Liverpool, UK P. Gomes, Laboratório de Biologia Molecular (LMCBM, SPC, CHLO-HEM), Lisbon, Portugal and Centro de Investigação Interdisciplinar Egas Moniz (CiiEM), Instituto Universitário Egas Moniz, Caparica, Portugal F. Incardona, EuResist Network, Roma, Italy – IPRO, Roma, Italy R. Kaiser, University of Cologne, Cologne, Germany R. Paredes, Irsicaixa, Spain B. Rossetti, University Hospital of Siena, Siena, Italy M. Sayan, Kocaeli University, Medical Faculty, Turkey A. Sönnerborg, Karolinska Institutet, Stockholm, Sweden A. M. Vandamme, REGA Institut KU Leuven, Belgium M. Zazzi, University of Siena, Siena, Italy. Publisher Copyright: © 2022 British HIV Association. |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022-08-30T22:38:15Z 2022-08 2022-08-01T00:00:00Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10362/143388 |
url |
http://hdl.handle.net/10362/143388 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
1464-2662 PURE: 46201318 https://doi.org/10.1111/hiv.13262 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
16 application/pdf |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799138104569757696 |